Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ERIC L SIMPSON

Allopathic & Osteopathic Physicians Dermatology

NPI
1972511426
CMS profile
362051
Location
PORTLAND, OR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$216,670.40

237 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Eli Lilly and Company $49,728.87 60
PFIZER INC. $44,305.43 24
SANOFI-AVENTIS U.S. LLC $42,460.34 29
Regeneron Healthcare Solutions, Inc. $19,237.62 11
GENZYME CORPORATION $18,509.56 14
ABBVIE INC. $9,534.93 25
LEO Pharma AS $9,470.52 28
Lilly USA, LLC $7,230.30 8
DERMIRA, INC. $7,093.23 21
UCB SA $2,799.73 12
Bausch Health US, LLC $2,194.87 2
LEO Pharma Inc. $1,965.00 1
Novartis Pharmaceuticals Corporation $1,440.00 1
Regeneron Pharmaceuticals, Inc. $700.00 1

Page 3 of 5; records 101–150 of 237 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ERIC L SIMPSON

NPI 1972511426 · CMS profile ID 362051

Allopathic & Osteopathic Physicians / Dermatology

PORTLAND, OR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 237 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1972511426?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ERIC L SIMPSON, NPI 1972511426, CMS profile ID 362051. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 237 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1972511426?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). ERIC L SIMPSON, NPI 1972511426, CMS profile ID 362051. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 237 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1972511426?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
ERIC L SIMPSON, NPI 1972511426, CMS profile ID 362051, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 237 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1972511426?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

237 matching records · $216,670.40 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 237 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 237.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eli Lilly and Company $131.8709/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009073 CMS
Eli Lilly and Company $2.2109/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009209 CMS
Eli Lilly and Company $13.7909/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009211 CMS
Eli Lilly and Company $51.2409/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009213 CMS
Eli Lilly and Company $2.2109/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009215 CMS
Eli Lilly and Company $13.7909/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009217 CMS
Eli Lilly and Company $9.2309/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009219 CMS
Eli Lilly and Company $43.1309/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009221 CMS
Eli Lilly and Company $9.2309/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009223 CMS
Eli Lilly and Company $2.2409/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009225 CMS
Eli Lilly and Company $14.0209/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009559 CMS
Eli Lilly and Company $9.2309/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009561 CMS
Eli Lilly and Company $9.2309/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009563 CMS
Eli Lilly and Company $13.7909/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009565 CMS
Eli Lilly and Company $8,805.1309/19/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657794595 CMS
SANOFI-AVENTIS U.S. LLC $172.3809/13/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694207473 CMS
SANOFI-AVENTIS U.S. LLC $205.7009/11/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694207477 CMS
SANOFI-AVENTIS U.S. LLC $318.0008/28/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694207493 CMS
SANOFI-AVENTIS U.S. LLC $318.0008/28/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694207495 CMS
SANOFI-AVENTIS U.S. LLC $318.0008/28/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694207499 CMS
PFIZER INC. $330.0008/27/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673786475 CMS
PFIZER INC. $330.0008/27/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673786767 CMS
PFIZER INC. $149.9508/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672982403 CMS
PFIZER INC. $330.0008/21/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673786477 CMS
SANOFI-AVENTIS U.S. LLC $278.3108/21/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694207481 CMS
PFIZER INC. $1,250.0008/14/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672982409 CMS
PFIZER INC. $7,750.0008/05/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672982397 CMS
SANOFI-AVENTIS U.S. LLC $278.3108/05/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694207485 CMS
SANOFI-AVENTIS U.S. LLC $278.3108/05/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694207489 CMS
PFIZER INC. $243.2807/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672599999 CMS
PFIZER INC. $6,690.0307/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672600003 CMS
PFIZER INC. $334.1607/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672600121 CMS
PFIZER INC. $105.9107/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672600125 CMS
Regeneron Healthcare Solutions, Inc. $5,520.0006/05/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673477815 CMS
Regeneron Healthcare Solutions, Inc. $47.8806/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673477817 CMS
Regeneron Healthcare Solutions, Inc. $26.3206/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673477819 CMS
SANOFI-AVENTIS U.S. LLC $354.9005/27/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694056541 CMS
GENZYME CORPORATION $2,808.0005/22/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694209065 CMS
SANOFI-AVENTIS U.S. LLC $317.9005/21/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694056657 CMS
LEO Pharma Inc. $1,965.0005/08/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687272227 CMS
UCB SA $13.7005/03/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681635941 CMS
Regeneron Healthcare Solutions, Inc. $5,865.0005/01/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673477813 CMS
Regeneron Healthcare Solutions, Inc. $5,520.0004/30/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673477811 CMS
Regeneron Healthcare Solutions, Inc. $82.1304/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673477807 CMS
Regeneron Healthcare Solutions, Inc. $75.7104/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673477809 CMS
SANOFI-AVENTIS U.S. LLC $26.9604/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694016293 CMS
Regeneron Healthcare Solutions, Inc. $25.2504/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673477803 CMS
Regeneron Healthcare Solutions, Inc. $626.0004/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673477805 CMS
Eli Lilly and Company $26.5604/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657791359 CMS
Eli Lilly and Company $99.0004/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657798137 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $216,670.40 237
PY2020 $219,083.46 62
PY2021 $221,965.51 72
PY2022 $179,139.89 133
PY2023 $159,460.81 123
PY2024 $203,330.55 154
PY2025 $200,051.70 98

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $39,904.20 31
PY2025 Principal investigator $341,052.93 172
PY2024 Recipient $63,467.28 89
PY2024 Principal investigator $366,180.88 395
PY2023 Recipient $58,323.42 64
PY2023 Principal investigator $675,749.91 291
PY2022 Recipient $75,036.89 96
PY2022 Principal investigator $506,268.96 125
PY2021 Recipient $70,599.39 105
PY2021 Principal investigator $519,590.85 149
PY2020 Recipient $61,672.35 73
PY2020 Principal investigator $340,023.80 102
PY2019 Recipient $50,336.57 71
PY2019 Principal investigator $653,736.00 79

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

203 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 12/22/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133783
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 12/22/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133785
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 12/22/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133787
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 12/19/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133779
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $600.00 12/19/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133781
Principal investigator 1 ABBVIE INC. $12,735.52 12/16/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202417947
Principal investigator 1 ABBVIE INC. $1,712.50 12/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202417931
Principal investigator 1 SANOFI US SERVICES INC. $5,328.00 12/08/2025 Non-covered Recipient Entity
OREGON HEALTH SCIENCE UNIV PHS
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226092288
Principal investigator 1 ABBVIE INC. $11,002.03 12/04/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202417919
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,644.38 12/04/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133741
Recipient GENZYME CORPORATION $250.00 12/02/2025 Covered Recipient Physician A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Long-Term Safety of Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1226117226
Principal investigator 1 SANOFI US SERVICES INC. $12,142.00 12/02/2025 Non-covered Recipient Entity
OREGON HEALTH SCIENCE UNIV PHS
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226092293
Recipient Regeneron Pharmaceuticals, Inc. $353.57 12/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184122691
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 12/01/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133729
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 12/01/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133731
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 12/01/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133733
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 12/01/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133735
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $233.00 11/14/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133723
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $184.86 11/07/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133719
Recipient PFIZER INC. $1,400.00 11/06/2025 Covered Recipient Physician ABROCITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727017
Recipient PFIZER INC. $1,400.00 11/06/2025 Covered Recipient Physician ABROCITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727725
Principal investigator 1 ABBVIE INC. $3,325.00 10/28/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 1202417880
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $246.48 10/23/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133711
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 10/20/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133709
Principal investigator 1 SANOFI US SERVICES INC. $3,234.00 10/20/2025 Non-covered Recipient Entity
OREGON HEALTH SCIENCE UNIV PHS
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226092277
Recipient GENZYME CORPORATION $500.00 10/15/2025 Covered Recipient Physician A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Long-Term Safety of Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1226117210
Principal investigator 1 ABBVIE INC. $1,250.13 10/09/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202417845
Principal investigator 1 SANOFI US SERVICES INC. $1,370.00 10/06/2025 Non-covered Recipient Entity
OREGON HEALTH SCIENCE UNIV PHS
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226092247
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,330.98 10/03/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133701
Recipient Regeneron Pharmaceuticals, Inc. $1,881.05 10/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184122687
Recipient Regeneron Pharmaceuticals, Inc. $3,426.80 10/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184122689
Recipient Amgen Inc. $2,030.55 09/22/2025 Covered Recipient Physician A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Combination With Topical Corticosteroids and/or Topical Calcineurin Inhibitors in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-SHUTTLE) No dispute reported 06/30/2026 1246637314
Principal investigator 1 SANOFI US SERVICES INC. $8,947.45 09/22/2025 Non-covered Recipient Entity
OREGON HEALTH SCIENCE UNIV PHS
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226092233
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $600.00 09/18/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133699
Principal investigator 1 ABBVIE INC. $1,027.50 09/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202417771
Recipient PFIZER INC. $940.00 09/04/2025 Covered Recipient Physician ABROCITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727805
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $369.72 08/26/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133697
Recipient PFIZER INC. $3,200.00 08/25/2025 Covered Recipient Physician ABROCITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228726718
Principal investigator 1 SANOFI US SERVICES INC. $2,923.00 08/25/2025 Non-covered Recipient Entity
OREGON HEALTH SCIENCE UNIV PHS
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226092179
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 08/22/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133695
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 08/20/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133693
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,498.28 07/31/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133683
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $308.10 07/31/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133685
Recipient PFIZER INC. $3,200.00 07/30/2025 Covered Recipient Physician ABROCITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727683
Recipient PFIZER INC. $3,200.00 07/30/2025 Covered Recipient Physician ABROCITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727735
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $219.45 07/21/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133623
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $219.45 07/21/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133625
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $331.35 07/21/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133627
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $34.95 07/21/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133629
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $275.10 07/21/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133631
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $304.95 07/21/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133633
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $214.80 07/21/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133635
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $248.70 07/21/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133637
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $331.35 07/21/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133639
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $34.95 07/21/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133641
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $275.10 07/21/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133643
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $304.95 07/21/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133645
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $214.80 07/21/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133647
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $248.70 07/21/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133649
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $219.45 07/21/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133651
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $277.95 07/21/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133653
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $248.70 07/21/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133655
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $219.45 07/21/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133657
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $277.95 07/21/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133659
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $219.45 07/21/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133661
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $219.45 07/21/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133663
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $219.45 07/21/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133665
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $277.95 07/21/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133667
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $219.45 07/21/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133669
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $219.45 07/21/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133671
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $331.35 07/21/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133673
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $275.10 07/21/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133675
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $304.95 07/21/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133677
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $214.80 07/21/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133679
Principal investigator 1 SANOFI US SERVICES INC. $3,527.00 07/14/2025 Non-covered Recipient Entity
OREGON HEALTH SCIENCE UNIV PHS
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226092131
Principal investigator 1 ABBVIE INC. $450.00 07/10/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 1202417686
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,114.46 07/10/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133621
Principal investigator 1 SANOFI US SERVICES INC. $12,031.00 07/02/2025 Non-covered Recipient Entity
OREGON HEALTH SCIENCE UNIV PHS
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226092137
Principal investigator 1 SANOFI US SERVICES INC. $3,425.00 07/02/2025 Non-covered Recipient Entity
OREGON HEALTH SCIENCE UNIV PHS
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226092149
Principal investigator 1 SANOFI US SERVICES INC. $10,165.00 07/02/2025 Non-covered Recipient Entity
OREGON HEALTH SCIENCE UNIV PHS
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226092155
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 06/18/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133601
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 06/18/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133603
Principal investigator 1 ABBVIE INC. $7,467.50 06/17/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202417661
Principal investigator 1 ABBVIE INC. $1,986.50 06/17/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202417666
Recipient GENZYME CORPORATION $500.00 06/17/2025 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Multiple Dupilumab Dose Regimens Administered as Monotherapy for Maintaining Treatment Response in Patients With Atopic Dermatitis No dispute reported 06/30/2026 1226117201
Recipient GENZYME CORPORATION $250.00 06/17/2025 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Multiple Dupilumab Dose Regimens Administered as Monotherapy for Maintaining Treatment Response in Patients With Atopic Dermatitis No dispute reported 06/30/2026 1226117206
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $115.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133479
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $115.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133481
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $115.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133483
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $116.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133485
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $116.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133487
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $116.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133489
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $124.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133491
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $234.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133493
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133495
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133497
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133499
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133501
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133503
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $308.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133505
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $308.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133507
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $308.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133509
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $332.50 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133511
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $941.43 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133513
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $984.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133515
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $984.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133517
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $997.50 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133519
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133521
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133523
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133525
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $46.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133527
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,995.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133529
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $46.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133531
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $46.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133533
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,660.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133535
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,100.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133537
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133539
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $54.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133541
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $54.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133543
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $54.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133545
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $55.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133547
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.19 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133549
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.19 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133551
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.19 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133553
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $62.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133555
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $62.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133557
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $62.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133559
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $62.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133561
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $62.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133563
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $62.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133565
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $62.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133567
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $62.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133569
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $62.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133571
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133573
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $86.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133575
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $86.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133577
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $86.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133579
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $86.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133581
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $86.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133583
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $86.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133585
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $88.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133587
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $92.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133589
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $92.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133591
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $92.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133593
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $104.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133595
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $104.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133597
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $104.00 06/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133599
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $184.86 06/05/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133469
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,750.00 06/05/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133473
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $600.00 06/05/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133475
Principal investigator 1 ABBVIE INC. $359.63 06/03/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202417581
Recipient Regeneron Pharmaceuticals, Inc. $640.68 06/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184122685
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $369.72 05/22/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133453
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,000.00 05/22/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133455
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $600.00 05/22/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133457
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 05/22/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133459
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $800.00 05/22/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133461
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,200.00 05/22/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133463
Recipient PFIZER INC. $330.00 05/08/2025 Covered Recipient Physician ABROCITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228719533
Recipient PFIZER INC. $330.00 05/07/2025 Covered Recipient Physician ABROCITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228760993
Principal investigator 1 ABBVIE INC. $1,621.90 05/06/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 1202417542
Recipient Regeneron Pharmaceuticals, Inc. $247.50 05/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184122683
Principal investigator 1 SANOFI US SERVICES INC. $29,700.00 04/28/2025 Non-covered Recipient Entity
OREGON HEALTH SCIENCE UNIV PHS
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226092143
Recipient PFIZER INC. $3,200.00 04/26/2025 Covered Recipient Physician ABROCITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228752596
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,243.02 04/15/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133445
Principal investigator 1 ABBVIE INC. $800.00 04/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 1202417518
Principal investigator 1 ABBVIE INC. $3,325.00 04/10/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 1202417512
Principal investigator 1 ABBVIE INC. $11,520.00 04/03/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202417491
Recipient Regeneron Pharmaceuticals, Inc. $668.22 04/01/2025 Covered Recipient Physician AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184122677
Recipient Regeneron Pharmaceuticals, Inc. $2,600.70 04/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184122679
Recipient Regeneron Pharmaceuticals, Inc. $741.07 04/01/2025 Covered Recipient Physician A PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO <6 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184122681
Principal investigator 1 Eli Lilly and Company $7,988.40 03/27/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187874891
Principal investigator 1 Incyte Corporation $171.63 03/27/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1240487746
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $184.86 03/19/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133433
Principal investigator 1 ABBVIE INC. $19,338.10 03/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202417452
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $246.48 03/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133431
Principal investigator 1 ABBVIE INC. $2,414.64 03/07/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202417448
Recipient GENZYME CORPORATION $500.00 03/07/2025 Covered Recipient Physician An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients greater than or equal to 6 to less than 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 1226117217
Recipient GENZYME CORPORATION $250.00 03/07/2025 Covered Recipient Physician An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients greater than or equal to 6 to less than 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 1226117221
Principal investigator 1 ABBVIE INC. $296.55 03/06/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
M16-045 - Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 1202417437
Principal investigator 1 Incyte Corporation $6,900.00 03/05/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1240487766
Recipient Regeneron Pharmaceuticals, Inc. $2,553.75 03/01/2025 Covered Recipient Physician A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184122667
Recipient Regeneron Pharmaceuticals, Inc. $1,168.33 03/01/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY INVESTIGATING THE EFFICACY AND SAFETY OF MULTIPLE DUPILUMAB DOSE REGIMENS ADMINISTERED AS MONOTHERAPY FOR MAINTAINING TREATMENT RESPONSE IN PATIENTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184122669
Recipient Regeneron Pharmaceuticals, Inc. $190.38 03/01/2025 Covered Recipient Physician AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184122671
Recipient Regeneron Pharmaceuticals, Inc. $1,021.50 03/01/2025 Covered Recipient Physician A PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO <6 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184122673
Recipient Regeneron Pharmaceuticals, Inc. $928.64 03/01/2025 Covered Recipient Physician AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184122675
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,875.00 02/24/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133419
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $308.10 02/18/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133415
Principal investigator 1 ABBVIE INC. $1,712.50 02/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202417416
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,229.19 02/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133411
Principal investigator 1 Incyte Corporation $2,931.32 02/05/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1240487760
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $76,991.29 02/05/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
EFFECTS OF INTERLEUKIN (IL)-4/IL-13 BLOCKADE ON THE STRUCTURE AND FUNCTION OF CUTANEOUS SENSORY NERVES No dispute reported 06/30/2026 1184133405
Recipient Regeneron Pharmaceuticals, Inc. $1,061.46 02/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184122665
Recipient PFIZER INC. $940.00 01/30/2025 Covered Recipient Physician ABROCITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228760472
Principal investigator 1 Incyte Corporation $2,335.71 01/28/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 1240487773
Principal investigator 1 Incyte Corporation $845.51 01/23/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1240487741
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $744.74 01/21/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133395
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $776.40 01/17/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133393
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $665.00 01/13/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133389
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $665.00 01/13/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133391
Principal investigator 1 ABBVIE INC. $450.00 01/08/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
M16-045 - Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 1202417360
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $123.24 01/07/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184133387
Principal investigator 1 Incyte Corporation $1,600.00 01/04/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1240487752